echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Investigational Alzheimer's disease drug lecanemab receives US FDA Fast Track designation

    Investigational Alzheimer's disease drug lecanemab receives US FDA Fast Track designation

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 28, Eisai and Biogen announced that lecanemab, an investigational anti-amyloid beta (Aβ) fibril antibody for the treatment of early Alzheimer's disease (AD), has been approved by the U.


    In September 2021, Eisai began rolling submissions of a Biologics License Application (BLA) for lecanemab to the FDA under the accelerated approval pathway


    A Phase 3 clinical study of lecanemab Clarity AD in early AD is ongoing and completed enrollment in March 2021 with a total of 1,795 patients


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.